Mathew Samuel, MD
Rheumatology · Camp Hill, PANPI 1538178686
Payments from drug & device makers
Across 122 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$208
- Esperion Therapeutics, Inc.$188
- Boehringer Ingelheim$179
- Takeda Pharmaceuticals U.S.A., Inc.$157
- Novo Nordisk$119
- Biohaven Pharmaceutical Holding Company Ltd.$115
- plus $847 from 22 others
What the payments were for
- Food & beverage$1,814100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $208 |
| Esperion Therapeutics, Inc. | 14 | $188 |
| Boehringer Ingelheim | 14 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $157 |
| Novo Nordisk | 8 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $115 |
| Biohaven Pharmaceuticals, Inc. | 7 | $104 |
| Amarin Pharma, Inc. | 8 | $103 |
| AstraZeneca(2 entities) | 5 | $81 |
| Vifor Pharma, Inc. | 6 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Endo Pharmaceuticals Inc. | 3 | $47 |
| Smith+Nephew | 2 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Genentech USA, Inc. | 2 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| AbbVie | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Bayer | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| GSK | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $13 |
| Lundbeck LLC | 1 | $11 |
How this compares
$1,814 in reported general payments places this provider in the 45th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $81,554 |
| Hydroxychloroquine Sulfate | 97 | $3,786 |
| MethotrexateMethotrexate Sodium | 107 | $2,883 |
| Prednisone | 232 | $1,269 |
| Leflunomide | 11 | $592 |
| Alendronate Sodium | 34 | $332 |
| Allopurinol | 27 | $230 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Camp Hill
- Alan KivitzDuncansville$27.1M
- Peter MerkelRadnor$6.3M
- Rohit AggarwalPittsburgh$6.2M
- Alexis Ogdie-BeattyPhiladelphia$5.7M
- Jonathan MinerPhiladelphia$3.8M
- Siamak Moghadam-KiaPittsburgh$1.9M
- Frederick MurphyDuncansville$1.2M
- Gregory EmkeyWyomissing$1.2M
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.